Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAD | P27708 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603156 | 0.96 | — | — | |
| SCHEMBL6602740 | 0.96 | — | — | |
| SCHEMBL873651 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL28100978 | 0.93 | CAD (0.44) | CADCYP2D6ALOX15CYP1A2LMNA | |
| Lithium SCHEMBL29627538 | 0.93 | CAD (0.44) | CADCYP2D6ALOX15CYP1A2LMNA | |
| SCHEMBL25041399 | 0.80 | — | — | |
| SCHEMBL3625362 | 0.80 | — | — | |
| SCHEMBL829988 | 0.77 | CYP2D6 (0.40) | CADCYP2D6ALOX15CYP1A2LMNA | |
| SCHEMBL9392772 | 0.76 | — | — | |
| SCHEMBL25042354 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004096206-A2 | THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND A TACE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-1134215-B1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PHARMACIA CORPORATION | 2004-06-24 | — | — | US | disclosed |
| EP-1134215-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122011-A1 | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy | PTGES2, PTGS2, PTGIS | CAD 202/4885CYP2D6 3123/4885ALOX15 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.